Pindolol, (Visken, LB46). A new treatment for hypertension: report of a multicentric open study.
D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000605:Amino Alcohols / Q000008:administration & dosage / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007211:Indoles / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D010946:Plants, Medicinal; D011926:Rauwolfia / Q000627:therapeutic use; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D000605:Amino Alcohols; D000959:Antihypertensive Agents; D004232:Diuretics; D004338:Drug Combinations; D007211:Indoles; D004295:Dihydroxyphenylalanine